(In the message sent on January 16 at 1:08 p.m., the last sentence of the first paragraph was clarified. Eylea 8 milligrams is approved in the EU in nAMD and DME for treatment intervals of up to six months.)
BERLIN (dpa-AFX) – Bayer is now allowed to sell the high dosage of its eye drug Eylea in the European Union in a third indication. The European Commission has approved the drug in the 8-milligram dose for the treatment of patients with macular edema as a result of retinal vein occlusion (RVV), the pharmaceutical and agricultural chemical group announced on Friday. Eylea is one of the most important revenue generators in the pharmaceutical division of the DAX group and is already available in the EU in the 8-milligram dose with treatment intervals of up to six months against neovascular (wet) age-related macular degeneration (nAMD) and against diabetic macular edema (DME).
With a longer treatment interval – i.e. the break between two treatments – such eye medications become more attractive for patients because they have to be injected directly into the eye. The Swiss pharmaceutical company Roche has a competing product on the market with Vabysmo./mis/stk
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising